Payment overview · 2025
General Payments
$42,910.87
40 reported records · 6 companies
Healthcare provider profile · identity verified
Mitchell Eugene Whitehead, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PENSACOLA, FL · NPI 1427460526
Verified facts
What the public records show
CMS Open Payments records show Mitchell Eugene Whitehead, M.D. received $42,910.87 in general payments during 2025 across 40 reported records.
Kedplasma LLC accounted for 97.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dovato, Pifeltro, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 489 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Descovy by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Pifeltro by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kedplasma LLC | Unresolved — no canonical attribution shown | $42,000.00 | 97.9% | 12 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $391.68 | 0.9% | 5 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $327.23 | 0.8% | 17 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $90.00 | 0.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $70.07 | 0.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.89 | 0.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $42,000.00 | 12 |
| Food and Beverage | $910.87 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $177.56 | 14 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $129.51 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $90.00 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $70.07 | 3 | 2025 |
Source payment records
|
|||||
| DELSTRIGO Normalized: delstrigo |
Drug | Merck Sharp & Dohme LLC | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| DOVATO dovato |
2025 | Dovato | 2024 | 186 | exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
489 | 51 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
149 | 17 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
186 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 489 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 402 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 367 | 90 |
| Losartan Potassium | Losartan Potassium | 355 | 82 |
| Gabapentin | Gabapentin | 331 | 69 |
| Lisinopril | Lisinopril | 276 | 70 |
| Omeprazole | Omeprazole | 250 | 71 |
| Trazodone Hcl | Trazodone Hcl | 241 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 228 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 210 | 54 |
| Dovato | Dolutegravir Sodium/Lamivudine | 186 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 180 | 42 |
| Tramadol Hcl | Tramadol Hcl | 166 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 38 |
| Metformin Hcl | Metformin Hcl | 150 | 43 |
| Descovy | Emtricitabine/Tenofov Alafenam | 149 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 40 |
| Tivicay | Dolutegravir Sodium | 142 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 30 |
| Meloxicam | Meloxicam | 139 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 37 |
| Sertraline Hcl | Sertraline Hcl | 129 | 24 |
| Alprazolam | Alprazolam | 122 | 26 |
| Famotidine | Famotidine | 120 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 30 |
| Mirtazapine | Mirtazapine | 101 | 23 |
| Montelukast Sodium | Montelukast Sodium | 99 | 23 |
| Ozempic | Semaglutide | 93 | 15 |
| Methocarbamol | Methocarbamol | 87 | 27 |
| Acyclovir | Acyclovir | 85 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 21 |
| Bupropion Xl | Bupropion Hcl | 79 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 17 |
| Simvastatin | Simvastatin | 77 | 22 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 77 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 77 | 12 |
| Furosemide | Furosemide | 73 | 19 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 71 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 71 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 12 |
| Carvedilol | Carvedilol | 70 | 18 |
| Potassium Chloride | Potassium Chloride | 68 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 62 | suppressed |
| Eliquis | Apixaban | 62 | 13 |
| Juluca | Dolutegravir/Rilpivirine | 60 | suppressed |
| Diazepam | Diazepam | 59 | 11 |
| Mounjaro | Tirzepatide | 58 | 15 |
| Prezcobix | Darunavir/Cobicistat | 58 | suppressed |
| Allopurinol | Allopurinol | 56 | 14 |
| Buspirone Hcl | Buspirone Hcl | 55 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | suppressed |
| Isentress | Raltegravir Potassium | 54 | suppressed |
| Fluconazole | Fluconazole | 52 | 15 |
| Pifeltro | Doravirine | 52 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 50 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 11 |
| Metformin Hcl Er | Metformin Hcl | 48 | 14 |
| Testosterone | Testosterone | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 11 |
| Chlorthalidone | Chlorthalidone | 45 | suppressed |
| Ondansetron Odt | Ondansetron | 45 | suppressed |
| Valsartan | Valsartan | 43 | suppressed |
| Atenolol | Atenolol | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 12 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Ritonavir | Ritonavir | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 12 |
| Darunavir | Darunavir | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 27 |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 16 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 22 |
| Mupirocin | Mupirocin | 30 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Prednisone | Prednisone | 24 | 11 |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Efavirenz | Efavirenz | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Xyosted | Testosterone Enanthate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Clindamycin Phosphate | Clindamycin Phosphate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Serostim | Somatropin | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Adderall | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Edurant | Rilpivirine Hcl | 12 | suppressed |
| Etravirine | Etravirine | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lopinavir-Ritonavir | Lopinavir/Ritonavir | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $42,910.87 · 40 records | Kedplasma LLC | APRETUDE, DELSTRIGO, DOVATO, Dexcom G6 Transmitter, PIFELTRO, QULIPTA, RUKOBIA, UBRELVY, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dovato play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error